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Introduction
Cannabinoid receptors are seven transmembrane receptors (7TMRs) that couple to G proteins and are characterized into two subtypes, cannabinoid type 1 (CB 1 R) and type 2 (CB 2 R) receptors [1, 2] . CB 1 Rs are ubiquitously expressed in the central nervous system and bind the endogenous cannabinoids 2-archadinoylglycerol and anandamide, which mediate retrograde signaling elicited by endocannabinoids at GABAergic and glutamatergic presynaptic neurons [3, 4] . CB 2 Rs are found peripherally on circulating immune cells [5, 6] . Like most 7TMRs, CB 1 and CB 2 Rs are capable of adopting a number of distinct conformations that transduce G proteindependent and -independent signaling [7, 8] . G protein-dependent signaling occurs upon agonist binding to CBRs, followed by interaction with pertussis toxin sensitive G i/o proteins and regulation of a number of downstream intracellular effectors including adenylyl cyclase, inward rectifying K + channels and voltage gated Ca ++ channels [9] [10] [11] . Alternatively, CBR agonists also modulate G protein-independent signaling responsible for recruitment of the proximally located, intracellular scaffolding proteins ␤-arrestin 1 and 2 [12, 13] . While similar in homology [14] , ␤-arrestin 1 and 2 exhibit distinct functional properties. ␤-Arrestin 1 is primarily responsible for mediating MAP kinase signaling that includes regulation of p38 and ERK1/2 activity, while ␤-arrestin 2 participates in agonist-induced desensitization and down-regulation of CBRs [13] .
In recent years, many groups have developed novel compounds termed "biased ligands" that act selectively at respective 7TMRs [15] [16] [17] [18] . These biased ligands are pharmacologically unique because they stabilize subsets of receptor conformations that invoke distinct G protein-dependent or -independent signaling [19] . Currently, development of novel analgesics acting via CB1, -, ␦-and -opioid receptors is focused on identification of G proteinselective compounds that are devoid of ␤-arrestin 2 recruitment [7, 16, 20, 21] . Evidence suggests that analgesic compounds exhibiting bias for G protein signaling may exhibit reduced adverse effects when administered both acutely and/or chronically [21] . For example, ␤-arrestin 2-knockout mice acutely administered the CB 1 R partial agonist, 9 -tetrahydrocannabinol ( 9 -THC), display enhanced antinociception and hypothermia [12] . Furthermore, chronic treatment of ␤-arrestin 2-knockout mice with 9 -THC produces reduced levels of CB 1 R desensitization and down-regulation, as well as attenuated antinociceptive tolerance [12, 21] . Observations that both acute (e.g., antinociception) and chronic (e.g., development of tolerance) responses to 9 -THC are markedly improved in ␤-arrestin 2-knockout mice indicate that future development of cannabinoid agonists that bias CB 1 R signaling toward G protein, and away from ␤-arrestin 2 pathways, might exhibit significantly reduced adverse effects.
Several novel analgesics that act as G protein biased agonists via -, ␦-and -opioid receptors have been identified [15, 22, 23] , and some of these compounds have advanced to clinical trials [24] . Unfortunately, discovery of cannabinoid ligands that bias CB 1 R signaling has been minimal [21] . Although a number of structurally diverse classes of cannabinoid ligands have been developed [25] [26] [27] , CB 1 R agonists characterized to date exhibit relatively equivalent coupling to both G-protein and ␤-arrestin 2 pathways [28] . Our group recently characterized a novel class of indole quinulidinone (IQD) analogues that exhibit high nanomolar affinity for CB 1 Rs [29] , and act as partial to full CB 1 R agonists for modulation of the Gi/Go-coupled intracellular effector adenylyl cyclase [30] . Although IQD analogues have been shown to clearly couple CB 1 Rs to G protein-dependent pathways, the ability of compounds in this class to produce CB 1 R-mediated G protein-independent recruitment of ␤-arrestin 2 has yet to be determined.
Analogues based on the novel IQD structural scaffold [30] might bias coupling of CB 1 Rs towards either G protein or ␤-arrestin 2 signaling pathways. Therefore, the purpose of this study was to determine whether cannabinoid agonists in this class exhibit ligand bias at CB 1 Rs. Chinese hamster ovary (CHO) cells stably expressing human CB1Rs (hCB 1 R) were used to examine the ability of IQD analogues to modulate hCB1R coupling to G protein-dependent and -independent signaling pathways, and adult male NIH-Swiss mice were used to assess in vivo pharmacological effects using the cannabinoid tetrad assay.
Methods

Materials
IQD analogues PNR-4-20 and PNR-4-02 were synthesized as previously described [30] and were dissolved in 100% DMSO to 10 mM stock concentrations for in vitro assays. WIN-55,212-2, JWH-018, CP-55,940, and DAMGO were obtained from Tocris Bioscience (Bristol, United Kingdom). GTP␥S was purchased from EMD Chemical (Gibbstown, NJ). [ 3 H]CP-55,940 (52.6 Ci/mmol) was acquired from PerkinElmer (Waltham, MA) and [ 35 S]GTP␥S (1250 Ci/mmol) was obtained from American Radiolabeled Chemicals (St. Louis, MO). PathHunter TM enzyme fragment complementation (EFC) experimental reagent was purchased from DiscoverRx Corporation (Fremont, CA). All other reagents used were purchased from Fisher Scientific (Pittsburgh, PA).
Animals
The University of Arkansas for Medical Sciences institutional animal care and use committee (e.g., IACUC) approved the animal use protocol employed in this study. All efforts were taken to minimize animal suffering and reduce the number of animals used. Adult male NIH-Swiss mice (9 week old) were purchased from Harlan laboratories, Inc. (Indianapolis, Indiana). All animals were housed three per cage (15.24 × 25.40 × 12.70 cm 3 ) in a temperature-controlled room in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility. Room conditions were maintained at 22 ± 2 • C and 45-50% humidity, with lights set to a 12-h light/dark cycle. Animals were fed Lab Diet rodent chow (Laboratory Rodent Diet no. 5001, PMI Feeds, St Louis, MO) ad libitum until immediately before testing. All test conditions used groups of either five or six mice which were randomly assigned to experimental groups, and all mice were drug-naïve before testing.
Cell culture assays
CHO-K1 cells stably expressing wild-type recombinant human CB 1 receptors (CNR1) were purchased from DiscoverRx Corporation (Fremont, CA) and designated CHO-hCB 1 -Rx. CHO-K1 cells stably co-expressing human CB 1 receptors and ␤-arrestin 2 (ARRB2), each tagged with complementiary ProLink ® ␤-galactisidase enzyme fragments, were also obtained from DiscoverRx Corporation and designated as CHO-␤2-hCB 1 . CHO-K1 cells were stably transfected with the human -opiod receptor (MOR, CHO-hMOR) in our laboratory as previously reported [31] . CHO-␤2-hCB1 and CHO-hCB 1 -Rx cells were cultured in HAM's F-12 K media (ATCC, Manssas, VA) while the CHO-hMOR cell line was cultured in DMEM (Mediatech Inc., Manassas, VA). Media for CHO-␤2-hCB 1 cells contained 10% fetal calf serum (Gemini Bioproducts, Sacramento, CA), 0.5% penicillin/streptomycin (Invitrogen, Carlsbad, CA), 500 g/ml of geneticin (or G418; Sigma-Aldrich, St. Louis, MO) and 250 g/ml hygromycin B (Thermo Fisher Scientific, Waltham, MA), while media for CHO-hCB 1 -Rx and CHO-hMOR cell lines contained 10% fetal calf serum (Gemini Bioproducts, Sacramento, CA), 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA), and 250 g/ml of G418 (Sigma-Aldrich, St. Louis, MO). All cell types were cultured in a humidified chamber at 37 • C with 5% CO 2 , harvested when flasks were approximately 70% confluent, and only cells from passages 4-15 were used in all experiments.
Membrane preparation
Membranes were prepared as described previously [30] . Briefly, cell pellets from CHO-␤2-hCB 1 , CHO-hCB 1 -Rx and CHO-hMOR cells were homogenized separately with 10 complete strokes utilizing a 40 ml Dounce glass homogenizer in ice-cold buffer containing 3 mM MgCl 2 , 50 mM HEPES pH 7.4, and 1 mM EDTA. Homogenized samples were then centrifuged at 40,000 × g for 10 min at 4 • C. Supernatants were decanted and pellets were re-suspended in ice-cold buffer, homogenized again, and centrifuged similarly two additional times. After the last centrifugation step, supernatants were decanted and remaining cell membranes were re-suspended in ice-cold 50 mM HEPES, pH 7.4 to achieve an approximate protein concentration of 5 mg/ml. Membrane homogenates were divided into respective aliquots and stored at −80 • C for future use. A 100 l aliquot of each membrane preparation was removed prior to freezing and the protein concentration was determined using BCA TM Protein Assay (Thermo Fisher Scientific, Waltham, MA).
Competition receptor binding
Competition receptor binding was conducted as previously described [32] . In brief, respective reaction mixtures contained increasing concentrations of the non-radioactive competing ligands in a 50 mM Tris-HCl buffer (pH 7.4) with 0.1% bovine serum albumin, 0.2 nM [ 3 H]-CP-55,940, 5 mM MgCl 2 , and either 50 g of CHO-␤2-hCB 1 or 100 g of CHO-hCB 1 -Rx membrane homogenates. The total volume of the incubation mixture was 1 ml. All reactions were mixed and allowed to reach equilibrium binding via incubation at 37 • C for 15 min. Non-specific binding was defined as the amount of radioligand binding remaining in the presence of a 1 M concentration of the non-radioactive, high affinity, non-selective CBR agonist WIN-55,212-2. Binding was terminated via rapid vacuum filtration through glass fiber filters (Brandel, Gaithersburg, MD), followed by four 5 ml washes of ice-cold 50 mM Tris-HCl (pH 7.4) buffer containing 0.1% bovine serum albumin. Four ml of Scintiverse © scintillation fluid (Fisher Scientific, Waltham, MA) was added to respective filters and radioactivity was quantified 24 h later utilizing a Packard-Tri-carb 2100/TR liquid scintillation counter (PerkinElmer, Shelton, CT).
[ 35 S]GTP S binding
The GTP␥S binding assay was used to measure G-protein activation, as previously described [33] . Briefly, 25 g of CHO-hCB 1 -Rx or 50 g of CHO-hCB 1 -Rx and CHO-hMOR membrane homogenates were added to reaction mixtures containing 10 mM MgCl 2 , 20 mM HEPES, 100 mM NaCl, 0.1 nM [ 35 S]GTP␥S, 10 M GDP, 0.1% bovine serum albumin and the specified concentrations of ligand to be examined. The total volume of the incubation mixture was 1 ml. After mixing each solution, reaction mixtures were incubated at 30 • C for 30 min. Nonspecific binding was defined by the amount of radioactivity remaining in the presence of 1 M non-radiolabeled GTP␥S. Reactions were terminated by rapid vacuum filtration through glass fiber filters followed by four washes with 5 ml of ice cold 50 mM HEPES (pH 7.4) containing 0.1% bovine serum albumin. Four ml of Scintiverse © scintillation fluid (Fisher Scientific, Waltham, MA) was added to the filters and the amount of radioactivity was quantified 24 h later utilizing a Packard-Tri-carb 2100/TR liquid scintillation counter (PerkinElmer, Shelton, CT).
Measurement of forskolin-stimulated intracellular cAMP levels in intact cells
CHO-␤2-hCB 1 or CHO-hMOR cells were plated separately into 24-well plates at a density of 7 × 10 6 cells/plate and incubated overnight in the respective culture media previously described at 37 • C in 5% CO 2 . The next day, culture media was gently removed from each well and replaced with 500 l pre-incubation mixture containing either HAM's F-12 K (CHO-␤2-hCB 1 ) or DMEM (CHO-hMOR) with 2 Ci/well [ 3 H]adenine, 0.9% NaCl, and 500 M 3-isobutyl-1-methylxathine (IBMX), as previously reported [30] . Cells were subsequently incubated for 3 h at 37 • C. The preincubation mixture was removed and specified concentrations of each respective ligand were added to the individual wells for 15 min at 30 • C in a Krebs-Ringer-HEPES solution (110 mM NaCl, 10 mM HEPES, 55 mM sucrose, 25 mM glucose, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , pH 7.4) containing 10 M forskolin and IBMX. Reactions were terminated by adding 50 l 2.2N HCl and [ 3 H]cAMP was extracted utilizing alumina column chromatography. Radioactivity contained in 4 ml of the final column eluate was counted by a Packard-Tri-carb 2100/TR liquid scintillation counter after adding 10 ml of liquid scintillation cocktail.
ˇ-Arrestin 2 recruitment assay
␤-Arrestin 2 recruitment assays were conducted utilizing CHO-␤2-hCB 1 cells according to the manufacturer's protocol (DiscoveRx Corporation, Fremont, CA) with minor modifications. Specifically, CHO-␤2-hCB 1 cells were seeded into 384-well plates at a density of 5000 cells/well in 10 l of supplied Cell Plating Reagent 0 (DiscoveRx) and incubated overnight at 37 • C in 5% CO 2 . Initial optimization experiments determined that the relatively small incubation volume (10 l) does not significantly decrease due to evaporation after overnight incubation. Lack of media evaporation is likely due to culture of cells in a humidified incubator. The next day, vehicle and drug dilutions, each containing 5% DMSO, were prepared in Cell Plating Reagent 0 at the indicated concentrations. Two and onehalf l of respective drugs were added to quadruplicate wells of CHO-␤2-hCB 1 cells and incubated for 90 min at 37 • C in 5% CO 2 . A final 1% DMSO concentration was achieved upon drug addition to CHO-␤2-hCB1 cell wells. Following incubation, detection reagent (DiscoveRx) was prepared by combining 19 parts of Cell Assay Buffer, 5 parts Substrate Reagent 1, and 1 part Substrate Reagent 2. Six l of prepared detection reagent was then added to each well containing vehicle or drug-treated CHO-␤2-hCB 1 cells and was allowed to incubate at room temperature for 1 h. Following incubation, luminescence was determined by a SpectraMax ® Plus plate reader (Molecular Devices Corporation, Sunnyvale, CA).
2.9. CB 1 receptor desensitization and down-regulation following chronic treatment CHO-␤2-hCB 1 and CHO-hCB 1 -Rx cells were plated in culture media into 6-well plates at a density of 7 × 10 6 cells/plate and incubated overnight at 37 • C in 5% CO 2 . The next day, media was removed and each well was washed three times with 6 ml of serum free HAM's F-12 K media. Following the last wash, 6 ml of serum free HAM's F-12 K media, and a receptor saturating concentration (e.g., >10X the K i value) of CP-55,940 (10 −7 M) or PNR-4-20 (10 −5 M) was added to each well and incubated for increasing durations of 0 min, 30 min, 1 h, 2 h, 3 h and 10 h. After drug incubation, cells were washed three times with 6 ml of serum free HAM's F-12 K media. Following the last wash, 1 ml of PBS/EDTA was added to each well and incubated at 37 • C in 5% CO 2 for 15 min. Cells were then harvested with cell scrapers and collected into 1.5 ml micro-tubes and centrifuged at 10,000 rpm for 10 min. After centrifugation, PBS/EDTA was removed and cell pellets were stored at −80 • C for future use.
Reduction in CB 1 receptor density following chronic drug treatment (e.g., receptor down-regulation) was quantified by competition binding assays as previously described (see Methods 2.5 
In vivo cannabinoid tetrad analysis
PNR-4-20 (1, 3, and 10 mg/ml) and rimonabant (1 mg/ml) were prepared in a vehicle containing 1% EtOH, 7.8% tween-80, and 91.2% saline. Mice were individually injected with a constant volume of 0.1 ml/g with a dose of 10, 30, or 100 mg/kg for PNR-4-20 or 10 mg/kg for rimonabant. All vehicle and drug solutions were sonicated for 15 min prior to administration. As previously described [34] , mice were administered an intraperitoneal (i.p.) injection of PNR-4-20 and tested 35 min later. Mice were tested sequentially for all four measures of the cannabinoid tetrad, in the following order; 1) hypothermia, 2) analgesia, 3) catalepsy and 4) suppression of locomotor activity. Briefly, hypothermia was measured utilizing a digital thermometer (model BAT-12, PhysiTemp, Clifton, NJ) equipped with a Ret-3 mouse probe (model 50314, Stoelting Co., Dale, IL) inserted rectally to a depth of approximately 2 cm. Temperature readings were obtained within 8 s. Analgesia was measured as tail-flick latency using the EMDIE-TF6 radiant heat apparatus (Emdie Instrument Co., Montpelier, VA). Mice were carefully positioned on the stage of the apparatus, while the tail was extended into a groove to break a photobeam. Starting at time = 0, a timer and radiant heat source directed onto the dorsal surface of the tail, approximately 2 cm from its origin from the body, were initiated. Movement of the tail after the beginning of the trial broke the photobeam, stopped both the heat source and the timer, and ended the trial. To prevent tissue damage, the maximum allowed time of each trial was set to 10 s. Catalepsy was measured by the horizontal bar test, using a tubular steel bar (0.5 cm in diameter) that was supported 4.0 cm above and horizontal to a covered platform. To begin each trial, mice were placed into a species-atypical position with hindlimbs on the covered platform and forelimbs on the horizontal bar. Upon placement on the catalepsy bar, a timer was started, and counted until the mouse removed both paws from the bar. The maximum time allowed on the bar was 30 s. Lastly, locomotor activity was measured using polycarbonate activity boxes (26.67 cm × 20.96 cm × 15.24 cm), in which the bottom of each box was marked and divided into four equally-sized quadrants. Each mouse was placed into a separate activity box, and quadrant crossings (all four limbs crossing one of the boundaries) were scored for 5 min using an overhead video camera. Between experimental observations, boxes were sprayed and wiped with Coverage Plus NPD (Steris Healthcare, Mentor, OH), and dried with paper towels.
3.1. Tolerance to hypothermic effects in chronically treated mice NIH Swiss were weighed and administered i.p. injections of either saline, 3 mg/kg JWH-018, 30 mg/kg 9 -THC, or 100 mg/kg PNR-4-20 for 5 consecutive days. Rectal temperatures were measured each day (using the same procedure as described earlier in Methods section 3) 1-h after injection of saline, 9 -THC and JWH-018, and 35-min after PNR-4-20 administration. After the 5th injection, animals were subjected to a 7-day washout where no injections were administered. On day 7 of the washout, animals were again injected with the same dose of the same compound they were previously administered for the 5-day chronic study, and were reassessed for drug-induced effects on rectal temperature.
Rimonabant precipitated withdrawal
NIH Swiss mice were chronically administered saline, 3 mg/kg JWH-018, or 100 mg/kg PNR-4-20 once per day for 5 consecutive days via i.p. injection. On the 5th day of drug injections, animals received 10 mg/kg rimonabant 75 min after the injection of saline or JWH-018, and 50 min after the injection of PNR-4-20. As previously described [35, 36] , immediately following the rimonabant injection, mice were placed in a circular, transparent glass vessel (radius 4.25 cm, height 16 cm) sealed with a ventilated cover and closely observed for withdrawal signs (front paw tremor, face rubbing and back paw rearing) for 60 min. Scoring the observed withdrawal signs was accomplished by counting the frequency of front paw tremors and recording the duration of face rubbing and rearing behaviors. Between groups of mice, observation vessels were sprayed and wiped with Coverage Plus NPD (Steris Healthcare, Mentor, OH), and dried with paper towels.
Statistical analyses
GraphPad Prism version 7.03 (GraphPad Software Inc., La Jolla, CA) was utilized for all curve-fitting and statistical analyses. Each in vitro data point presented in all figures is represented as the mean ± S.E.M. (Standard Error of the Mean) from a minimum of 4 individual experiments. Three-parameter nonlinear regression for one-site competition was used to determine the IC 50 for competition receptor binding. IC 50 values were subsequently converted to K i values (a measure of receptor affinity) by the Cheng-Prusoff equation [37] . Four-parameter non-linear regression was used to analyze concentration-effect curves to determine the EC 50 or IC 50 (measures of potency) and E max or I max (measures of efficacy) for GTP␥S binding and adenylyl cyclase or ␤-arrestin 2 recruitment, respectively. All dissociation constants and measurements of potency were converted to pK i , pEC 50 , or pIC 50 values by taking the negative log of each value so that parametric tests could be used for statistical comparisons. Statistical comparisons between treatment groups (i.e., dose of PNR-4-20) in the tetrad experiments were performed using one-way analysis of variance (ANOVA) tests followed by Tukey's HSD multiple comparisons tests. Multiple ANOVAs within each data set were corrected using a Bonferroni adjustment such that statistical significance was declared at p < 0.025 2-tail . Statistical comparisons between treatment groups in the tolerance and withdrawal experiments were performed using a two-way mixed-measures analysis of variance (ANOVA) with treatment group serving as the between-subjects factor and test day serving as the within-subjects factor. Dunnett's or Tukey's HSD multiple comparisons tests (or simple main effects tests in the case of a statistically significant interaction) were performed to compare treatment groups to saline control or for all pairwise comparisons. Last, a one-way ANOVA was performed to compare withdrawal signs between treatment groups, followed by Tukey's HSD multiple comparisons tests. Statistical significance for all mea- sures recorded in the tolerance and withdrawal experiments was declared at p < 0.05 2-tail .
Biased hCB 1 R signaling was determined by comparing the intrinsic activity of agonists to activate G-proteins, inhibit forskolin-stimulated cAMP accumulation, and recruit ␤-arrestin 2 in transfected CHO cells. Specifically, transduction ratios [log(/K A )] for each test ligand in all assays were calculated from full concentration-effect curves fit by GraphPad Prism (version 6.0 h) to the Black-Leff operational model of agonism [38] employing a user defined equation as detailed in Westhuizen et al. [39] . In this arrangement of the model, log(/K A ) is a composite parameter made up of two distinct parameters; K A is defined as the equilibrium affinity constant (K A ) and tau is defined as a combination of receptor density and the coupling efficiency of the agonist. In this specific form of the model, the tau and K A parameter values are not the primary endpoint of the fit. The model is expressed in order to produce the unique log(/K A ) value for each agonist without solving either of the parameters directly. Where indicated, a competitive operational model of bias was used to analyze a subset of data. This was included because it has been shown that, in some cases, this model is able to produce a reduction in the error of the estimated log(/K A ) values [40] . The calculated log(/K A ) values were used to provide a single parameter value for reported intrinsic activity assessments of each respective test ligand in each assay examined. The full non-biased hCB 1 R agonist CP-55,940 was used as the reference compound for comparison in all studies.
To calculate a normalized transduction coefficient [e.g., the log(/K A ) ratio] for a test ligand in each assay, the log(/K A ) for the reference agonist CP-55,940 was subtracted from the log(/K A ) for each test ligand of interest, as shown in Eq. (1): (1) The resulting log(/K A ) ratio for each respective test ligand was next used to determine the relative efficiency or favorability of that compound to evoke a distinct receptor-mediated response when comparing two different functional assays [e.g., the log(/K A ) ratio]. This was calculated by subtracting the log(/K A ) ratio determined for the test ligand in one functional assay, from the log(/K A ) ratio determined for the same test ligand in a second functional assay, as shown in Eq. (2):
Finally, the log(/K A ) ratio was used to calculate the bias factor for each test ligand for modulation of the two different functional assays examined, as shown in Eq. (3): Table 1 . Each data point presented represents the mean ± S.E.M. from a minimum of 4 individual experiments.
Results
IQD analogues PNR-4-20 and PNR-4-02 bind hCB 1 Rs expressed in CHO-ˇ2-hCB 1 cells with high nanomolar affinity
The structures of cannabinoids agonists examined in this study are presented in Fig. 1 , and represent compounds derived from the structurally distinct non-classical ( Fig. 1A ; CP-55,940), naphthoylindole ( Fig. 1B ; JWH-018) and indole quinulidinone ( Fig. 1C ; PNR-4-20 and Fig. 1D ; PNR-4-02) classes [29, 41] . Initial competition binding studies, employing the high affinity CB 1 /CB 2 R agonist [ 3 H]CP-55,940 [42] , were conducted to determine the affinity of the cannabinoid ligands examined (Fig. 2) for hCB 1 Rs expressed in CHO-␤2-hCB 1 cells. The affinity of all compounds for hCB 1 1 Rs with a rank order (from highest to lowest) of CP-55,940 = JWH-018 > PNR-4-02 = PNR-4-20. These data indicate that the novel IQD analogues PNR-4-20 and PNR-4-02 bind with high affinity to hCB 1 Rs expressed in CHO-␤2-hCB 1 cells.
Initial studies with PNR-4-20 [30] , referred to as compound number 5 in that report, exhibited an affinity of 9.3 nM for mouse CB 1 Rs. Curiously, in the present study the affinity of PNR-4-20 for human CB 1 Rs was determined to be 159 nM. In addition to the Table 1 G protein-dependent and -independent signaling for hCB1Rs expressed in CHO-␤2-hCB1 and CHO-hCB1-Rx cells. NA -not applicable: PNR-4-02 was unable to produce sufficient levels of ␤-arrestin 2 recruitment to allow for quantification of concentration-effect curves. Table 1 . Each data point presented represents the mean ± S.E.M. from a minimum of 4 individual experiments.
obvious species difference, differences in batch-to-batch purity of PNR-4-20 and/or vehicles used for drug solubilization might have contributed to the magnitude of the observed differences in the affinity of PNR-4-20 for CB 1 Rs between studies.
PNR-4-20 and PNR-4-02 potently and efficaciously couple hCB 1 Rs to G protein-dependent signaling pathways in CHO-ˇ2-hCB 1 cells
Agonist binding to CB 1 Rs initiates a number of signaling cascades that occur via both G i/o protein-dependent and -independent mechanisms [44, 45] . G protein-dependent effects arise from agonist stabilization of distinct CB 1 R conformations that couple to G i/o proteins, resulting in modulation of the activity of downstream effectors including K + channels, Ca ++ channels and the enzyme adenylyl cyclase [46, 47] . Since all cannabinoid ligands examined ( Fig. 1) bind to hCB 1 Rs with high affinity (Fig. 2) , experiments were next conducted to determine the ability of these compounds to activate G proteins, the first step in G i/o protein signaling pathways ( Fig. 3A; Table 1 ). G i/o protein activity was quantified in membranes prepared from CHO-␤2-hCB 1 cells incubated with the non-hydrolysable, radioactive GTP ana-log [ 35 S]GTP␥S, and increasing concentrations of each ligand to be examined. Measures of potency (e.g., EC 50 ) and efficacy (e.g., E MAX ) were derived from full concentration-effect curves (Fig. 3A) and are presented in Table 1 Fig. 3A ; Table 1 ). The novel IQD analogues PNR-4-20 and PNR-4-02 also act as agonists to activate G proteins; however, with decreased potency when compared to CP-55,950 and JWH-018 (P > 0.05; Table 1 ). The rank order of potency for G protein activation is identical to the rank order of affinity for CB 1 Rs. CP-55,940, JWH-018, and PNR-4-20 act as full CB 1 R agonists to activate G proteins (e.g., E MAX values of 1.03 ± 0.06, 1.02 ± 0.10, and 1.02 ± 0.10 fractional units, respectively). By contrast, PNR-4-02 exhibits only partial agonist activity in this assay (e.g., E MAX value of 0.62 ± 0.01 fractional units; P < 0.05; Table 1 ) and the fit of PNR-4-02 data to the operational model produces a log affinity (pEC 50 ) estimate of 7.66 ± 0.04. These results indicate that CP-55,940, JWH-018, and the IQD analogues PNR-4-20 and PNR-4-02 all act as CB 1 R agonists to activate G proteins in CHO-␤2-hCB 1 membranes.
To provide an additional measure of efficacy for G proteindependent signaling produced by the cannabinoid ligands examined, the ability of all compounds to modulate activity of the intracellular effector adenylyl cyclase via hCB 1 Rs expressed in intact CHO-␤2-hCB 1 cells was measured ( Fig. 3B ; Table 1 ). Agonist binding to CB 1 Rs results in activation of G i/o proteins that then inhibit activity of the downstream effector adenylyl cyclase, resulting in a reduction in levels of intracellular cAMP [11, 50] . Consistent with actions of an agonist, and results observed for G protein activation (Fig. 3A) (Fig. 3B) . Measures of potency (e.g., IC 50 values) and efficacy (e.g., I MAX values) derived from the best fit of the concentration-effect curves are presented in Table 1 . To allow for use of parametric test for statistical comparisons, IC 50 values were converted to pIC 50 values (pIC 50 = −Log [IC 50 ]). Similar to the rank order of hCB 1 affinity (Fig. 2) and potency for G protein activation (Fig. 3A) , the rank order of potency to modulate adenylyl cyclase activity is CP-55,940 > JWH-018 > PNR-4-20 = PNR-4-02 (P < 0.05; Table 1 ). Interestingly, unlike that observed for G protein activation in which PNR-4-02 exhibits partial agonist activity (Fig. 3A) , all cannabinoid ligands act as full agonists to modulate adenylyl cyclase activity in intact CHO-␤2-hCB 1 cells.
To verify that the G protein-dependent effects observed for the cannabinoid ligands examined are due to specific interaction with hCB 1 Rs, G protein activation and modulation of adenylyl cyclase activity studies were conducted in CHO cells devoid of hCB 1 Rs, but instead stably expressing human -ORs (e.g., CHO-hMOR cells). As expected, in membranes prepared from CHO-hMOR cells, the full -opioid agonist DAMGO 1 Rs to G protein-independent signaling pathways via recruitment of -arrestin 2 in CHO-ˇ2-hCB 1 cells
Functional assessment thus far has revealed that CP-55,940, JWH-018, PNR-4-20, and PNR-4-02 all couple hCB 1 Rs to G i/o protein-dependent signaling pathways. Although the standard paradigm for pharmacological assessment of novel hCB 1 R ligands examines coupling to G protein-dependent signaling pathways, G protein-independent signaling can also be revealed by quantifying the ability of ligands to recruit ␤-arrestin 2, a proximal scaffolding protein originally associated with GPCR desensitization and downregulation [13] . Agonist recruitment of ␤-arrestin 2 by hCB 1 
Initial optimization experiments were conducted to determine the time-dependent characteristics of ␤-arrestin 2 recruitment produced by incubation with the reference agonist CP-55-940 and test ligand PNR-4-20 (Fig. 4A ). For these experiments, ␤-arrestin 2 recruitment was measured following 0-180 min incubation of CHO-␤2-hCB 1 cells with CP-55,940 or PNR-4-20. Results showed that ␤-arrestin 2 recruitment produced by both CB1 agonists occurs in a time-dependent manner with maximal effects observed approximately between 90-120 min. Based on these observations, all other experiments investigating ␤-arrestin 2 recruitment were conducted 90 min following drug administration. To confirm that recruitment of ␤-arrestin 2 by CP-55,940 and JWH-018 in this cellular model occurs through a hCB 1 R-mediated mechanism, coincubation of these CB 1 R agonists (10 −6 M) with the high affinity CB 1 -selective antagonist rimonabant (10 −5 M) completely eliminates ␤-arrestin 2 recruitment produced by both agonists ( Fig. 4C ; P < 0.01) (Fig. 4B) .
Results from full concentration-effect curves demonstrate that CP-55,940 and JWH-018 potently (e.g., EC 50 values of 54.1 nM and 78.1 nM, respectively) and efficaciously (e.g., E MAX of 1.04 ± 0.17 and 1.16 ± 0.16 fractional units, respectively) recruit ␤-arrestin 2 in CHO-␤2-hCB 1 cells ( Fig. 5A; Table 1 ). In marked contrast, the IQD analogue PNR-4-20 recruits ␤-arrestin 2 with significantly lower potency (e.g., EC 50 value of 5412 nM) and efficacy (e.g., E MAX value of 0.24 ± 0.02 fractional units) ( Table 1 ; P < 0.05). Furthermore, the second IQD compound examined, PNR-4-02, is unable to produce sufficient levels of ␤-arrestin 2 recruitment to allow for quantification.
CP-55-940 and PNR-4-20 both bind to hCB 1 Rs with nanomolar affinity ( Fig. 2; Table 1 ), yet only CP-55,940 produces efficacious recruitment of ␤-arrestin 2 (Fig. 5A) . If recruitment of ␤-arrestin 2 by CP-55,940 occurs via interaction with hCB 1 Rs, then it would be predicted this recruitment should be reduced by co-incubation with PNR-4-20 (Fig. 5B) . In fact, it is possible to quantitate this interaction at the shared orthosteric site using a specific form of the operational model [40] . With this model, it is possible to produce an accurate mechanistic understanding of the relative efficacy of PNR-4-20 ( Fig. 5B; Table 2 ).
A second IQD compound examined, PNR-4-02, was unable to produce sufficient levels of ␤-arrestin 2 recruitment to allow for quantification (Fig. 5A) . It is possible to analyze the competitive nature of this ligand and demonstrate that PNR-4-02 nevertheless Data derived from the concentration-effect curves presented in Figs. 3A (G-protein activation), 3B (adenylyl cyclase modulation) and 5 (␤-arrestin 2 recruitment) were fit to the Black-Leff operational model of agonism [38] to provide log(/K A ) ratios, a single parameter measure of intrinsic activity of each respective test compound in each assay examined [38, 39] . In the ␤-arrestin 2 recruitment assay the data was fit without ( binds to CB 1 Rs with sufficient affinity to antagonize the agonistmediated recruitment of ␤-arrestin 2 by CP-55,940 (10 −7 M) and completely reverses this response in a concentration-dependent manner by co-incubation with PNR-4-02 (10 −7 to 10 −4 M) (Fig. 5C) . From this analysis, it is possible to produce an affinity value for PNR-4-02 using the Cheng and Prusoff method [37] . The log affinity (pK i ) of PNR-4-02 produced by this method in the ␤-arrestin 2 recruitment assay of 5.749 ± 0.092 (Fig. 5C ) is strikingly different than the affinity estimate (pEC 50 ) produced from G protein activation of 7.29 ± 0.09 ( Fig. 3A; Table 1 ).
PNR-4-20 and PNR-4-02 act as highly G protein biased CB 1 R agonists
The marked differences in potency and efficacy (Table 1 ; P < 0.05) of PNR-4-20 and PNR-4-02 to modulate G protein- Table 3 Log( /K A ) ratios and bias factors for cannabinoid agonists at CB1Rs expressed in CHO-␤2-hCB1 cells. log(/K A ) ratios (see Table 2 ) were used to determine the relative efficiency or favorability of a given compound to evoke a distinct receptor-mediated response when comparing two different functional assays [e.g., the log(/K A ) ratio]. This was calculated by subtracting the log(/K A ) ratio determined for the test ligand in one functional assay, from the log(/K A ) ratio determined for the same test ligand in a second functional assay. The resulting log(/K A ) ratios are presented along with the 95% confidence interval, in parentheses, to highlight the degree of confidence as to whether the mean values do, or do not, overlap zero. The specified log(/K A ) parameters were employed to calculate the bias factor for each compound of interest by the following equation; 10 log(/KA)ratio [38, 39] . Note: PNR-4-02 was unable to produce sufficient levels of ␤-arrestin 2 recruitment to allow for quantification of Log( /K A ) ratios and bias factors and thus are not included in this table. dependent (e.g., G protein and adenylyl cyclase activity) versus G protein-independent (e.g., ␤-arrestin 2 recruitment) signaling pathways ( Figs. 3 and 5 ; Table 1 ), suggest that the IQD analogs PNR-4-20 and PNR-4-02 act as G protein biased CB 1 R agonists. To establish and quantify the degree of bias produced by the IQD analogues and JWH-018, data derived from the concentration-effect curves (Figs. 3 A, B and 5 A) were fit to a form of the Black-Leff operational model of agonism [38, 52] to provide log(/K A ) ratios (Table 2 ). These ratios were used to provide a single parameter value for efficacy assessments of each respective ligand in each assay examined [38, 39] . When CP-55,940 was used as the reference compound for comparison in all studies, a normalized transduction coefficient log(/K A ) was produced in each assay (Table 2) as the log(/K A ) for the reference agonist subtracted from the log(/K A ) for each test compound of interest (e.g. JWH-018, PNR-4-20 and PNR-4-02). The resulting log(/K A ) ratio for each respective test compound (Table 2 ) was used to compare the relative efficiency of that compound to evoke a distinct receptor-mediated response when comparing two different functional assays. The difference in the log(/K A ) ratio, or log(/K A ) ratio for test the agonist, is a direct representation of this comparison (Table 3 ). This was calculated by subtracting the log(/K A ) ratio determined for the test compound in one functional assay from the log(/K A ) ratio determined for the test compound in the second functional assay. Finally, the log(/K A ) ratio was used to calculate the bias factor for each compound of interest by the following equation; 10 log(/KA)ratio (Table 3) .
GTP␥S/␤-
Bias factors comparing G protein-dependent (e.g., G protein activation and adenylyl cyclase modulation) and G proteinindependent (e.g., ␤-arrestin 2 recruitment) signaling demonstrate that the commonly abused full CB 1 agonist JWH-018 produces little CB 1 R bias for coupling to either of these signaling pathways (Table 3 ). More interestingly, the model suggests that the IQD analogue PNR-4-20 exhibits bias for both CB 1 R signaling toward G protein activation (e.g., bias factor of 5.4) and modulation of adenylyl cyclase activity (e.g., bias factor of 29.5), when compared to ␤-arrestin 2 recruitment. This difference of activity is supported by the observation that the 95% confidence intervals for the log(/K A ) of each response pair do not overlap the value of zero; a 95% confidence interval overlapping zero is viewed as a balanced agonist [8] .
The interpretation of the bias of PNR-4-02 is strikingly more complicated due to the lack of demonstrable agonist activity in the ␤arrestin-2 recruitment assay. This property results an artificial, undefined minimum value when fit using the operational model and leads to ambiguity when interpreting the relative activity of the ligand. For these reasons, it was reasonable to limit this interpretation by present the difference in affinity constants observed for PNR-4-02 in the systems where affinity could be estimated. A remarkable greater than 100-fold difference of affinity was observed for this ligand between the ␤arrestin 2 and G protein activation systems. This large difference in affinity is accompanied by PNR-4-02 demonstrating a profound inversion in rank efficacy with both greater and less efficacy than PNR-4-20. The difference in affinity combined with the inversion in rank order efficacy suggest it is unlikely that a simple two-state model is sufficient to explain these results. Taken as a whole, the evidence presented here suggests that the IQD analogues PNR-4-20 and PNR-4-02 are novel agonists that highly bias CB 1 R signaling toward G protein signaling over ␤-arrestin 2 recruitment. ␤-Arrestin 2 is a signaling molecule that historically has been shown to play an important role in desensitization and downregulation of many GPCR subtypes following chronic agonist exposure [53] . Specifically, upon prolonged agonist binding to GPCRs, translocation of certain G protein receptor kinases (GRKs) results in phosphorylation of specific intracellular serine and threonine residues of activated GPCRs. ␤-Arrestin 2 is then recruited to phosphorylated GPCRs, further interfering with G protein coupling and signaling (e.g., receptor desensitization), and eventually translocating GPCR-␤-arrestin 2 complexes to clathrin-coated pits that are internalized for either recycling (e.g., resensitization) and/or removal (e.g., receptor down-regulation) [13] . Because PNR-4-20 is a biased agonist that favors G protein-dependent signaling, while producing little interaction of CB 1 Rs with ␤-arrestin 2, it was hypothesized that chronic exposure of CHO-␤2-hCB 1 (Fig. 6) . As anticipated following exposure of CHO-␤2-hCB 1 cells to the full CB 1 R agonist CP-55,940 (10 −7 M), receptor density is reduced by 47 ± 7.1% after only 30 min, and maximally by 68.0 ± 1.2% after 2 h. In marked contrast, chronic treatment with the G protein biased CB 1 R agonist PNR-4-20 (10 −5 M) reduces CB 1 R density maximally at 2 h by only 39.7 ± 4.9%. Furthermore, although the general timecourse of CB 1 R down-regulation produced by both drugs appears similar, CP-55,940 produces greater reduction in CB 1 R density at every time point examined except the 30 min exposure period (P < 0.01). The observed differences in CB 1 R density cannot be explained by potential alteration in the affinity of the radioligand for CB 1 Rs produced by chronic drug exposure, because 10 h Experiments were next conducted to determine if PNR-4-20 produces similar effects predictive of a G protein biased agonist Table 1 . Each data point presented represents the mean ± S.E.M. from a minimum of 4 individual experiments.
in CHO-hCB 1 -Rx cells expressing fewer, non-tagged hCB 1 Rs and native ␤-arrestin. Specifically, CHO-hCB 1 -Rx cells were incubated with PNR-4-20 (10 −5 M) or non-biased agonist CP-55,940 (10 −7 M) for durations ranging from 0 to 10 h, followed by measurement of hCB 1 R density to detect down-regulation (Fig. 8A) . As observed in CHO-␤2-hCB 1 cells, exposure to CP-55,940 decreases hCB 1 R receptor density by 84.8 ± 3.1% after only 30 min, and completely eliminates receptor binding at 3 h. Also similar to that seen in CHO-␤2-hCB 1 cells, chronic treatment with PNR-4-20 (10 −5 M) only reduces hCB 1 R density maximally by 76.4 ± 3.6%, and CP-55,940 produces greater reduction in hCB 1 R density at every time point examined (P < 0.05-0.001). Very interestingly, exposure to PNR-4-20 for 10 h results in only 42.2 ± 1.7% reduction in binding, compared to greater levels of receptor down-regulation at earlier time points, indicating a potential trend towards return of hCB 1 R density to pre-drug treated levels. In addition to participating in hCB 1 R down-regulation, ␤-arrestin 2 recruitment also decreases the ability of hCB 1 Rs to couple to downstream signaling pathways, resulting in receptor desensitization [53] . Experiments were next conducted to compare the ability of PNR-4-20 and CP-55,940 to produce hCB 1 R desensitization in CHO-hCB 1 -Rx cells (Fig. 8B) . CHO-hCB 1 regulation and desensitization than prolonged treatment with non-biased agonist CP-55,940.
PNR-4-20 acts as an agonist in the cannabinoid tetrad in mice
As an initial step toward future development of biased CB 1 R agonists based on the IQD scaffold, a set of experiments was conducted to evaluate the effects of PNR-4-20 in the cannabinoid tetrad in mice to determine if PNR-4-20 exhibits in vivo cannabimimetic activity. CB 1 R cannabinoid agonists produce characteristic dose-dependent effects in a set of four biobehavioral endpoints when administered in rodents [e.g., hypothermia, antinociception, decreased locomotor activity, and increased catalepsy], referred to as the cannabinoid tetrad [55] . Similar to previous reports [34, 56] in this study NIHSwiss mice were injected intraperitoneally (i.p.) with vehicle, 10, 30, or 100 mg/kg PNR-4-20 and effects on cannabinoid tetrad endpoints were assessed. Pilot studies used radiotelemetry to assess hypothermic effects of PNR-4-20 at 5-min intervals and found that peak hypothermic effects were observed 35 min after injection (data not shown). As such, a 35 min pretreatment time was used for all subsequent in vivo studies. (Fig. 9D) . Results of the Tukey's HSD multiple comparisons tests for each endpoint are presented in Fig. 9A-D . Supporting a CB 1 Rmediated mechanism of action, co-administration of PNR-4-20 with the CB 1 R-selective antagonist rimonabant (10 mg/kg) resulted in a significant reversal of the effects of PNR-4-20 on rectal temperature and catalepsy. Together, these experiments indicate that the IQD analogue PNR-4-20 is a highly biased CB 1 R agonist that exhibits CB 1 R-mediated biobehavioral effects in mice when administered by the i.p. route.
Chronic PNR-4-20 injections result in less tolerance and dependence in mice
While investigating the in vivo function of PNR-4-20 in mice, additional studies were conducted in order to determine if the in vitro profile of chronic PNR-4-20 exposure is replicated in a chronic dosing animal paradigm. As previously observed, when two separate cell lines expressing the hCB 1 R were chronically exposed to PNR-4-20 at multiple time points, there was signifi- Fig. 10 . PNR-4-20 induces less tolerance and reduced antagonist-precipitated withdrawal following repeated exposure. NIH-Swiss mice were injected intraperitoneally (i.p.) with saline, 3 mg/kg JWH-018, 30 mg/kg 9 -THC, or 100 mg/kg PNR-4-20 and hypothermic effects were assessed following drug administration for five consecutive days [A] and following a 7-day drug-free break [B] . Following the recording of the thermoregulatory effects of test compounds on test day 5, all mice were observed for rimonabant-precipitated withdrawal for a 60 min period [43] . cantly less desensitization and downregulation of the hCB 1 R when compared to exposure of another full CB 1 R agonist. As such, drug naïve animals were chronically treated with saline, 3 mg/kg JWH-018, 30 mg/kg 9 -THC and 100 mg/kg PNR-4-20 for 5 consecutive days. Each day, rectal temperature was taken following the allotted drug pretreatment time. Results of Tukey's HSD tests and Dunnett's multiple comparisons tests are presented in Fig. 10A Fig. 10A and B presents the results of the tolerance experiments. Following the 5 injections, animals underwent a 7-day "washout" period where drug was not administered. When animals were re-injected with the same drugs on day 7 of the washout, all subjects except animals treated with PNR-4-20 exhibited persistent tolerance to cannabinoid-induced hypothermia when compared to the hypothermic effects observed following the initial injections (Fig. 10B) . Because chronic exposure to PNR-4-20 did not result in the development of persistent tolerance following a 7-day washout period, additional studies were conducted to determine if chronic exposure to PNR-4-20 might also result in decreased dependence, as indexed by assessing withdrawal signs following chronic agonist administration and challenge with 10 mg/kg rimonabant. Fig. 10C and D. Collectively, animals chronically treated for 5 days with 3 mg/kg JWH-018 then challenged with rimonabant exhibited robust withdrawal signs of front paw tremors and facial rubbing, which are indicative of cannabinoid withdrawal [35, 36, 58] . Interestingly, animals chronically injected with PNR-4-20 displayed no significant withdrawal signs when challenged with rimonabant in regard to paw tremors (Fig. 10C) , facial rubbing (Fig. 10D) , or rearing behaviors (data not shown), suggesting a reduced dependence liability with this compound. Overall, the in vivo effects observed with PNR-4-20 in regards to tolerance and withdrawal production indicate that cannabinoids that preferentially bias G protein signaling at the hCB 1 R could reduce the probability of drug-induced adverse effects.
Discussion
The current studies report initial pharmacological characterization of two analogues in a novel structural IQD class that function as highly biased hCB 1 R agonists. Specifically, it was shown that the IQD compounds PNR-4-20 and PNR-4-02 elicit G-protein signaling (as measured by G-protein activation and inhibition of forskolin-stimulated cAMP accumulation), with transduction ratios proximal to the non-biased full hCB 1 R agonist CP-55,940. However, in marked contrast to CP-55,940, both PNR-4-20 and PNR-4-02 produce little to no ␤-arrestin 2 recruitment. Indeed, the quantitative calculation of bias for the IQD analogue PNR-4-20 compared to the non-biased reference compound CP-55,940 revealed that this ligand favors G protein activation (5.4-fold) and adenylyl cyclase modulation (29.5-fold) over ␤-arrestin 2 recruitment. Furthermore, a second IQD compound, PNR-4-02, failed to produce sufficient recruitment of ␤-arrestin 2 to allow for quantification and thus might be anticipated to exhibit greater G protein bias that PNR-4-20. Although the functional selectivity of PNR-4-02 was more complicated to determine, the change in rank order efficacy of PNR-4-02 across multiple assay systems provides striking evidence that the ligand identifies several (more than two) states of the receptor and is also biased toward G protein activation.
As expected due to reduced ␤-arrestin 2 recruitment, chronic exposure of cells to PNR-4-20 results in significantly less hCB 1 R desensitization and down-regulation compared to similar treatment with CP-55,940. When tested in mice, PNR-4-20 (i.p.) is active in the cannabinoid tetrad and exerts its biological effects via CB 1 R activation in a dose-dependent manner. Chronic PNR-4-20 injections produce short-lived tolerance, and no significant withdrawal signs are observed following administration of the CB 1 R antagonist rimonabant. Finally, studies of a structurally similar analog PNR-4-02 show that it is also a G protein biased hCB 1 R agonist when tested in vitro. As reported previously for biased opioid agonists, cannabinoid agonists that bias hCB 1 R activation toward G-protein, relative to ␤-arrestin 2 signaling, may produce fewer and less severe adverse effects.
It is interesting to speculate on the activity of these test ligands considering their striking difference in activity between systems. As stated previously, the models are not sufficient to analyze agonists with minimal to no agonist activity in one of the test systems. In this case, it may only be possible to establish occupancy of the test ligand and, based on this occupancy determination, the predictions of a state model can be either accepted or excluded. A two-state model is insufficient to produce a change in rank order efficacy of a series of test ligands between different assay systems [59] . This conclusion is distinctly supported, in the case of PNR-4-02, by the demonstration of occupancy and the affinity constant established using the ChengPrusoff method [37] . Together these avenues of evidence indicate that PNR-4-02, and PNR-4-20, identify distinctly different states of the receptor in the spectrum of functional responses measured.
Current clinical use of cannabinoids is limited and underdeveloped [60] , emphasizing a critical need for discovery of novel drugs acting via hCB 1 Rs that target beneficial signaling pathways, while limiting adverse effects [12, 21, 61] . As such, development of biased hCB 1 R agonists for future therapeutic use holds tremendous promise. Biased ligands acting at several GPCR classes are in various stages of drug development, with some in clinical trials for a variety of disease states that are generating encouraging results. For example, a G protein biased -OR agonist (TRV130) produces potent and efficacious analgesia (due to G protein-dependent signaling), while exhibiting significantly less -OR mediated respiratory depression and gastrointestinal dysfunction (due to reduced G protein-independent signaling via ␤-arrestin 2 recruitment) when compared to morphine [15] . Biased ligands acting at several other GPCRs, including ␦-opioid [16, 62] , -opioid [17] , angiotensin II type I [63] , serotonergic [64] [65] [66] and ␤-adrenergic type I and II receptors [67, 68] are also being characterized. These studies investigating biased signaling at GPCRs other than cannabinoid receptors, identify an important gap in our knowledge that could be used to advantage in the preclinical development of similar compounds that specifically interact with cannabinoid receptors [16] . Therefore, discovery of biased hCB 1 Rs agonists derived from the novel IQD scaffold reported herein represents a significant and novel approach towards the development of safe and efficacious cannabinoid drugs for clinical use.
The present studies reveal that PNR-4-20 and PNR-4-02, two analogues belonging to a novel class of cannabinoid ligands known as the IQDs [29, 30] , are highly G protein biased agonists at hCB 1 Rs. When compared with non-biased hCB 1 R agonists CP-55,940 and JWH-018, PNR-4-20 and PNR-4-02 exhibit similar efficacy for coupling hCB 1 Rs to G protein-dependent signaling pathways, while drastically differing from these agonists in eliciting ␤-arrestin 2 recruitment via hCB 1 Rs. Studies examining hCB 1 R down-regulation and desensitization in response to prolonged exposure to hCB 1 R biased agonists focused on PNR-4-20, because this analogue acts as a full agonist in all assays examined. Comparing agonists with similar efficacy (to avoid potential confounding effects) is a common approach employed by many studies characterizing the pharmacological actions of biased agonists acting at other classes of GPCRs [15, 17, 62, 67, 68] . However, it should be noted that while PNR-4-02 acts as a partial agonist for G protein activation, it exhibits full agonist activity for modulation of adenylyl cyclase activity. The full agonist activity of PNR-4-02 observed in the adenylyl cyclase assay is likely because the endpoint being measured (e.g., forskolinstimulated cAMP production) is an amplified response, occurring downstream relative to G protein activation (the first step in the signaling cascade). In any case, the observed partial, as opposed to full, agonist activity of PNR-4-02 at hCB 1 Rs might actually present a potential therapeutic advantage for the development of drug candidates in this structural class. The partial hCB 1 R agonist properties of 9 -THC (the primary psychoactive component in cannabis) have been proposed to potentially result in fewer and less severe adverse effects associated with marijuana use than those produced by full hCB 1 R agonist synthetic cannabinoids present in abused K2/Spice products [69] . Therefore, development of biased hCB 1 R partial agonists might ultimately be found to improve the safety profile of these novel cannabinoid receptor ligands.
Previous studies investigating the biased -OR agonist, TRV130, reveal that in vitro observations pertaining to preferential G protein-dependent signaling over ␤-arrestin 2 recruitment translated to fewer adverse effects (e.g., respiratory depression and inhibition of gastrointestinal motility) measured in vivo [15] . As such, because non-biased, full agonists (e.g., JWH-018) at hCB 1 Rs produce tolerance and dependence following chronic administration [70] , this study tested if PNR-4-20 would exhibit diminished levels of these adverse effects. In vivo studies revealed that chronic PNR-4-20 treatments result in less persistent tolerance to cannabinoid-induced hypothermia while producing no significant withdrawal behaviors when challenged with a CB 1 R antagonist. Although the lower efficacy of PNR-4-20 observed in mice, when compared to JWH-018, could initially explain the absence of long-term tolerance development and blunted withdrawal behaviors, compounds equivalent in efficacy in vivo, like 9 -THC, produced significant persistent tolerance in our chronic treatment studies and has been shown to precipitate withdrawal following rimonabant injection [36, 58, 71] . Therefore, the in vitro signaling properties of PNR-4-20 characterized at hCB 1 Rs do seem to extend to physiological function in regards to exhibiting blunted tolerance and dependence in vivo, and could potentially give newly developed IQD analogues therapeutic value devoid of adverse effects Biased hCB 1 R agonists derived from the IQD scaffold could prove to be clinically useful to treat a variety of disease states. Preclinical research studies demonstrate that drugs acting at hCB 1 Rs show promise for treatment of disease states including chronic pain [72] , cancer [73] , nausea [74] , stroke [75] , heart disease [76] and epilepsy [77] . Clinical reports also demonstrate that hCB 1 R agonists appear to provide therapeutic effects as analgesics [78] , antiemetics [74] , anti-convulsants [79] and appetite-stimulants [80] . Drug development of cannabinoid-based therapeutics is unfortunately limited by several adverse effects produced by drugs in this class, including the development of tolerance [81] , dependence [81] [82] [83] and withdrawal [82] in response to prolonged cannabinoid administration. For example, 7-day administration of 9 -THC [84] [85] [86] or JWH-018 [87] to mice results a progressive loss in response to cannabinoid-induced hypothermia, antinociception, and locomotor activity (e.g., development of tolerance). Although research into the molecular mechanisms underlying these adaptive responses is ongoing, tolerance in response to chronic 9 -THC administration appears to result, in part, from recruitment of ␤-arrestin, leading to CB 1 R desensitization and down-regulation [12, 88, 89] . Importantly, acute administration of 9 -THC to ␤-arrestin 2-knockout mice produced enhanced antinociception and hypothermia when compared to wild-type mice, and chronic exposure resulted in reduced levels of CB 1 R desensitization and down-regulation, as well as attenuated antinociceptive tolerance [12, 21] . Since both acute (e.g., antinociception) and chronic (e.g., development of tolerance) responses to 9 -THC are improved in ␤-arrestin 2-knockout mice, the future drug development of cannabinoid agonists such as IQD-derived PNR-4-20 and PNR-4-02 that bias CB 1 R signaling toward G protein, and away from ␤-arrestin 2 pathways, might result in clinically effective drugs with significantly reduced adverse effects.
Although development of biased hCB 1 R agonists based on the IQD scaffold appears promising, several sub-optimal characteristics of the specific analogues examined in this study need to be addressed. First, a relatively high dose (e.g., 100 mg/kg, i.p.) of PNR-4-20 is required to observe in vivo effects in the cannabinoid tetrad. While several factors might contribute to this observation, unfavorable pharmacokinetic properties should be considered. For example, as observed following administration of some opioids [90, 91] , rapid phase I metabolism of PNR-4-20 by CYP450 enzymes might inactivate the parent drug, reducing circulating levels of bioactive drug available. Poor drug solubility, inadequate systemic absorption of PNR-4-20 and/or failure to adequately cross the blood-brain-barrier to reach the sites of action in the CNS might also explain the high dose required in the tetrad experiments. In addition to pharmacokinetic properties, several pharmacodynamic issues should be addressed during drug-optimization studies for IQD-derived hCB 1 R biased agonists. For instance, the affinity of PNR-4-20 and PNR-4-02 for hCB 1 Rs was relatively low (e.g., 73-159 nM; Table 1 ) compared to the low nM range for receptor affinities observed for most FDA-approved drugs. It is possible that such low hCB 1 R affinity might have also contributed to the high dose required to observe in vivo effects of PNR-4-20. Lastly, both PNR-4-20 and PNR-4-02 bind relatively non-selectively to hCB 1 and hCB 2 Rs [29] , and thus improvement of hCB 1 R selectivity should be addressed in future optimization studies. In this respect, future structure-activity relationship studies employing the IQD scaffold should focus on generating high affinity, highly selective, bioactive, G protein biased hCB 1 R agonists with reduced adverse effects relative to currently available cannabinoid receptor therapeutics.
Conclusions
The data presented herein reveal that the IQD analogues PNR-4-20 and PNR-4-02 exhibit nanomolar affinity for hCB 1 Rs and act as highly biased G protein agonists when examined in vitro. As anticipated due to reduced coupling to ␤-arrestin 2, chronic exposure to PNR-4-20 results in less hCB 1 R desensitization and down-regulation when compared to the non-biased CB 1 R agonist CP-55,940. Lastly, PNR-4-20 (i.p.) is active in the cannabinoid tetrad in mice and chronic treatment results in development of less persistent tolerance and no significant withdrawal signs when compared to animals repeatedly exposed to the non-biased full agoinst JWH-018 or 9 -THC. Collectively, it is predicted that cannabinoid agonists developed from the IQD scaffold, that bias CB 1 receptor activation toward G protein relative to ␤-arrestin 2 signaling, will produce fewer and less severe adverse effects both acutely and chronically than currently available non-biased cannabinoid agonists.
